– Bloomberg
Solid Biosciences Will Offer Update On Long-Term Outcomes Data From Patients In Ongoing IGNITE Duchenne Muscular Dystrophy Phase 1/2 Trial OF SGT-001
- Functional and patient-reported outcomes data for the first three patients in the high-dose (2E14 vg/kg) cohort (Patients 4-6) 1.5 years post-dosing to be presented at the World Muscle Society 2021 Virtual Congress
